CD30/TNFRSF8 Antibody (115705) [Alexa Fluor® 405]

• Applications: WB, ELISA(Cap), ELISA(Det)
• Clone: 115705
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 405

CD30/TNFRSF8 Antibody (115705) [Alexa Fluor® 405] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse CD30/TNFRSF8
  Phe19-Thr281
  Accession # Q60846
• Specificity: Detects mouse CD30/TNFRSF8 in ELISAs and Western blots. In sandwich immunoassays, no cross-reactivity or interference with recombinant mouse (rm) TNF RI/TNFRSF1A, recombinant human (rh) TNF RI/TNFRSF1A, rhTNF RII/TNFRSF1B, rmTNF‑ alpha /TNFSF2, rhTNF‑
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair)
  • ELISA Detection (Matched Antibody Pair)
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD30/TNFRSF8 Antibody (115705) [Alexa Fluor® 405]

• CD30 antigen
• CD30
• CD30KI-1
• CD30L receptor
• cytokine receptor CD30
• D1S166EKi-1
• Ki-1 antigen
• Lymphocyte activation antigen CD30
• TNFRSF8
• tumor necrosis factor receptor superfamily member 8
• tumor necrosis factor receptor superfamily, member 8

Background

CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). Mature mouse CD30 consists of a 264 amino acid (aa) extracellular domain (ECD) with three cysteine-rich repeats, a 27 aa transmembrane segment, and a 190 aa cytoplasmic domain (3). In contrast, human CD30 includes an additional 90 aa in the ECD and contains six cysteine-rich repeats. Within common regions of the ECD, mouse CD30 shares 53% and 80% aa sequence identity with human and rat CD30, respectively. CD30 is normally expressed on antigen‑stimulated Th cells and B cells (4‑6). However, it is upregulated in Hodgkin’s disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). CD30 signaling costimulates antigen‑induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response (8). In the absence of antigenic stimulation, it can still induce T cell expression of IL-13 (9). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4⁺CD8⁺ T cells (10, 11). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). An 85‑90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q60846()